Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
about
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionEfficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trialDevelopment of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, MozambiquePregnancy and virologic response to antiretroviral therapy in South AfricaHIV-1 Genetic Variability and Clinical ImplicationsHIV-1 genetic variation and drug resistance development.Women's rights and women's health during HIV/AIDS epidemics: the experience of women in sub-Saharan Africa.Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrSystematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infantsPersistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineEvolution and molecular epidemiology of subtype C HIV-1 in ZimbabweEstimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.Antiretroviral therapies in women after single-dose nevirapine exposure.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south IndiaNevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapyEmergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype CRole of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.Surveillance of HIV drug resistance in children receiving antiretroviral therapy: a pilot study of the World Health Organization's generic protocol in Maputo, Mozambique.Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates
P2860
Q24235500-E3226000-40A2-4EE1-845D-2DB0627D9D4BQ24243146-F82B0B87-B464-489F-840D-6F8603C2E14EQ28476329-BE088956-C79A-433D-A940-324D75611214Q28546418-C97E92EA-1EB5-4F52-95F1-350DBBDB16DBQ28741879-75614132-EFB8-4489-B7C5-5F2C00EE6487Q30352010-127C9C47-9B02-4648-AB5B-A49B5F4156B4Q30354857-B09D1F29-BFA3-4754-A834-879CDE158589Q30378638-C8F4604F-05B9-43E8-95DD-9DE784B47653Q33267065-E966CDD4-D9E8-4BF9-B446-9096BB7B6199Q33284135-2A57DE62-A2B4-48A1-AB3E-BFCC7B08AC9CQ33294899-D6A9532D-0606-4D63-AAB8-EA8ED7B67858Q33396553-222B0CCE-2965-4A10-B694-68BE7E6601AEQ33396950-37D1DC3B-2610-4594-82BC-033231327594Q33605273-497AD60D-4EB1-4239-862E-C9A3D634EFCBQ33798282-0BF7D1C6-BFC3-4D9C-9BFF-4EE0B4E4329CQ34033166-AE0A6902-A027-454C-A206-122D40E5DAB7Q34071112-0962E838-8CEA-4193-9655-5BEC46460005Q34073190-4377D89F-8B42-413A-94BA-EF804C6A6D2CQ34120725-F8BA0F59-5C48-4882-BF8A-49BFA678AE44Q34363980-5EAF55F6-143D-4B70-B3B1-DFA52BC989ECQ34483505-5BC227AC-3CC3-4828-974D-9DFB217D1ECEQ34530060-D2251B6C-48F8-4CC4-8E50-E3003A479B62Q34572571-1D5A495E-D115-48CA-A9CB-70BE7942038AQ34631738-DD3A143D-EC85-46C1-8902-C62144A2ABCDQ34726928-031950AB-9FBB-4E94-95E5-8068E73D483BQ34764036-D74FEB4D-D19F-4C0C-9EC4-904CA93899A8Q34933329-05BA7816-CD87-4DDF-8701-E0F8122AFF69Q35187157-1B7E8096-6B00-4D60-BDB9-D75FB0E06C9AQ35260403-72AF6DBA-2A8A-4E0D-99A5-9595B7C70C20Q35260590-0AD05F04-D252-4E3E-B707-12A2881F0333Q35632898-556FE13A-237C-4C05-8F7F-C67DAF4FFFEBQ35682303-5AD1C5F5-40EC-4C16-8CC9-1894B280CAE1Q35790256-9AA48A80-4517-4C1A-8A55-D960B7D76C0EQ35868716-7ECB43D3-D705-4267-B931-7DCAB4336512Q35960319-B8F37785-83DA-4CDD-8B97-E399CAE054B0Q36077418-7BF3E81E-D6F7-4424-9BED-FE7599C716C7Q36429712-CA8F9868-3B5F-4C2A-BF90-87BA700CCC9DQ36611206-EDA1F02E-E3DF-4891-9643-EB23699B0E48Q36833511-EF844D1A-1ED9-434C-90CA-E3551BAD6732Q37115730-7CDD9809-EFC3-4060-9534-D30A092F5629
P2860
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Nevirapine (NVP) resistance in ...... nistration of single-dose NVP.
@en
type
label
Nevirapine (NVP) resistance in ...... nistration of single-dose NVP.
@en
prefLabel
Nevirapine (NVP) resistance in ...... nistration of single-dose NVP.
@en
P2093
P50
P356
P1476
Nevirapine (NVP) resistance in ...... nistration of single-dose NVP.
@en
P2093
Anthony Mwatha
Donald R Hoover
Francis Mmiro
J Brooks Jackson
Laura A Guay
Philippa Musoke
Sarah E Hudelson
Susan A Fiscus
P356
10.1086/430764
P407
P577
2005-06-01T00:00:00Z